This mini-review synthesizes current evidence on Trp-Kyn microdomains in the HNSCC TME and discusses therapeutic opportunities that move beyond single-enzyme inhibition, including dual IDO1/TDO2 targeting, AhR antagonism and biomarker-guided combination regimens to restore antitumor immunity. The gene discussed is AHR; the disease is head and neck squamous cell carcinoma.